White Paper AGA: Drug Development for Eosinophilic Esophagitis.

@article{Hirano2017WhitePA,
  title={White Paper AGA: Drug Development for Eosinophilic Esophagitis.},
  author={Ikuo Hirano and Stuart Spechler and Glenn T Furuta and Evan S. Dellon},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2017},
  volume={15 8},
  pages={
          1173-1183
        }
}
Since first characterized in 2 small case series in the early 1990s, eosinophilic esophagitis (EoE) has emerged as a commonly identified cause of esophageal symptoms in children and adults.1,2 Although several highly effectively dietary, pharmacologic, and endoscopic therapies have been reported, none is currently approved by either the US Food and Drug Administration (FDA) or European regulatory authorities. Evolving diagnostic criteria have challenged drug development, in particular the… CONTINUE READING
BETA
9
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 98 REFERENCES

Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring.

  • Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

PedsQL eosinophilic esophagitis module: feasibility, reliability, and validity.

  • Journal of pediatric gastroenterology and nutrition
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Eosinophilic Esophagitis in Children and Adults.

  • Gastrointestinal endoscopy clinics of North America
  • 2018
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…